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Thyroid cancers are the most common endocrine malignancy. Radiation exposure, family history of
thyroid cancer and some inherited conditions are the most important predisposing factors for the
development of thyroid cancer. Three mitogenic signalling pathways have been described in the thyroid
cell, which are inﬂuenced by various stimulatory and inhibitory hormones, growth factors and neuro-
transmitters. Various proto-oncogenes and oncogenes like ras, braf, trk,met and RET also play a role in the
signal transduction systems. Two theories have been described in thyroid cancer pathogenesis, the foetal
cell carcinogenesis theory and the more common, multistep carcinogenesis theory.
The multistep carcinogenesis theory is now the accepted model in many human cancers, including
thyroid cancer. The early events of tumour formation are the consequence of activation of either various
growth factors or the proto-oncogenes like ras, met or ret. This results in the formation of differentiated
thyroid cancers like the papillary, follicular or Hurthle cell cancers. The later stages of tumour formation
involve further activation of proto-oncogenes and loss or inactivation of tumour suppressor genes like
p53. Based on this theory, follicular carcinomas are generated from follicular adenomas and papillary
carcinomas from precursor cells generated from thyrocytes. Anaplastic carcinoma may develop from
papillary or follicular carcinoma by dedifferentiation. In this review article, we highlight the molecular
pathogenesis of thyroid tumours.
 2010 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Thyroid cancer is the most common endocrine malignancy and
usually originates from the follicular cell, except medullary cancer.
In England and Wales, thyroid cancer accounts for less than 0.5
percent of all cancers and results in about 250 deaths per year.1
Studies have shown that the incidence of thyroid cancer is
increasing worldwide2,3 and this increase is predominantly in
papillary thyroid cancer. Between 1973 and 2003, the incidence of
papillary thyroid cancer rose by 189 percent in the USA.3 The
apparently increased incidence is probably the result of better early
detection of small cancers.
Various risk factors have been implicated in the pathogenesis of
thyroid cancers and these include – radiation exposure, inherited
conditions predisposing to thyroid neoplasia and, other factors like
diet, pre-existing goitre, effect of hormones and occupation have
also linked to thyroid cancer. Thyroid cancers develop as a result of
a multistep process, consistent with the multistep carcinogenesis
theory, which will be the focus of this review.).
iates Ltd. Published by Elsevier Lt2. Mitogenic pathways in the regulation of thyroid growth
and function
The thyroid gland is composed of follicular cells which consti-
tute about 70 percent of the gland, endothelial cells which consti-
tute about 20 percent of the gland and the rest formed by
ﬁbroblasts. In a normal adult, the weight and composition of the
gland remain fairly constant, with cell turnover about 6–8 renewals
in adult life.4 The growth of cells in the thyroid is closely regu-
lated,5,6 with the thyrocyte controlling the functions of other cells
through secretion of paracrine factors like ﬁbroblast growth factor
(FGF) and insulin-like growth factor I (IGF-I).5
Abnormal proliferation leads to disease states like goitre,
adenomas or carcinomas, whilst hypoplasia can lead to hypothy-
roidism. Thyroid follicular cells undergo differential growth
patterns with different rates of growth within the same thyroid
gland due to different patterns of growth factor responsiveness,
thereby leading to the goitrous state. With further stimulation by
growth factors over time, focal hyperplasia may result.7
In the thyroid gland, three distinct mitogenic pathways (Fig. 1.)
have been well deﬁned namely: the hormone receptor–adenylate
cyclase–cAMP protein kinase A system (AC/cAMP/PKA), thed. All rights reserved.
Fig. 1.
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hormone receptor–phospholipase C cascade (PLC) pathway.
TSH is the major stimulator of the AC/cAMP/PKA pathway by
interacting with the TSH-receptor (TSH-R). Binding of TSH to TSH-R
activates Gsa and adenylate cyclase, which results in the generation
of cAMP, and further activates protein kinase A (PKA). This cascade
accounts for TSH-mediated regulation of function, differentiation
and proliferation of the thyroid gland.8,9
In the receptor tyrosine kinase (RTK) pathway, ligand binding of
RTK by epidermal growth factor receptor (EGFR), a product of the
erb B proto-oncogene.10 EGF stimulates the PLC–PKC–calcium
systems,11 and mainly the ras pathway, which ﬁnally leads to an
increased transcriptional activity. EGF also stimulates the increased
expression of c-fos and c-myc oncogenes.12
The PLC cascade pathway is activated by TSH binding, neuro-
transmitters, circulating growth factors and phorbol ester,
mediated via the TSH-R and PKC receptor. The activation of TSH-R
leads to increased PLC activity, resulting in the formation of inositol
1,4,5-triphosphate (IP3) and diacylglycerol (DAG), which then
subsequently increases the intracellular calcium and PKC activity.
About a 1.2–2 fold increase in PLC activity has been shown in
response to TSH in normal, benign and early thyroid cancers, with
no increase detected in invasive or metastatic cancers.13
3. Models of thyroid carcinogenesis
Two models of thyroid carcinogenesis have been described, the
foetal carcinogenesis theory and the common, multistep carcino-
genesis theory.
4. Foetal cell carcinogenesis theory
The foetal cell carcinogenesis theory was proposed by Takano.14
The theory hypothesises that cancer cells are derived from the
remnants of foetal thyroid cells. The foetal thyroid cells are rarely
seen in normal thyroid development, whereas once the foetal cells
are transformed into cancer cells, the cells are no longer under
control. According to the foetal cell theory, genomic changes do notplay any role in the foetal cell carcinogenesis, unless the genomic
changes prevent the foetal cells from differentiation.15
The three proposed origins of the thyroid cancer cells are,
prothyrocytes, thyroblasts and thyroid stem cells.16 The thyroblasts
express thyroglobulin and oncofoetal ﬁbronectin (onfFN), do not
form follicles, and are the precursor cells for papillary cancer. The
prothyrocytes are more differentiated than ﬁbroblasts, express
thyroglobulin (Tg) mRNA but not onfFN and form thyroid follicles.
According to this theory, papillary thyroid cancers are formed from
thyroblasts. Follicular thyroid cancers are formed from prothyr-
ocytes and anaplastic cancers from thyroid stem cells.
5. Multistep carcinogenesis theory
According to the multistep carcinogenesis theory, most cancers
are clonal in origin, arising from a single abnormal cell and progress
as a result of number of inheritable alterations.17 This model has
been supported by evidence from clinical and experimental models
and is now the accepted model in many human cancers. The
sequential event in cancer pathogenesis was originally shown
convincingly in colorectal carcinoma by Vogelstein et al.18
Based on the multistep carcinogenesis theory, follicular carci-
nomas are generated from follicular adenomas and papillary
carcinomas from precursor cells generated from thyrocytes.
Anaplastic carcinoma may develop from papillary or follicular
carcinoma by dedifferentiation. The ideas are illustrated in Fig. 2.
The various factors involved in the development and progression of
follicular cell derived thyroid cancers are discussed in the next few
sections.
6. Molecular pathogenesis of papillary thyroid cancer
Papillary thyroid cancer accounts for up to 70–90 percent of the
differentiated thyroid cancer types. They are commoner in women
and peak in the second and third decade of life. The tumours are
usually slow growing, unencapsulated and metastasize to the
regional lymph nodes. They are multifocal in about 30 percent of
cases and in about 30 percent of patients; palpable lymph nodes
Fig. 2. Multistep carcinogenesis model of thyroid cancer formation. Formation of benign thyroid tumours occurs as a result of alteration of various growth factors. The follicular
neoplasms are formed from thyrocytes by mutations of ras and other factors as shown in the ﬁgure. Papillary cancers are formed by alterations in RET/PTC and other oncogenes. The
undifferentiated tumours are formed from the differentiated tumours by mutations of tumour suppressor genes.
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presence of branching papillae with ﬁbrovascular core, lined by
a single layer of cells. The nuclear features include the presence of
large pale staining cells, with an Orphan Anne eye nucleus and
nuclear grooving. The predisposing factors for the development of
sporadic papillary thyroid cancer are: history of irradiation to the
head and neck region,20,21 Hashimoto’s thyroiditis,22 familial
adenomatous polyposis23 and Cowden’s syndrome. There are three
major genetic alterations in PTC, involving that of the RET, RAS and
BRAF genes, which is discussed below. The frequency of the genetic
alterations is shown in Table 1.
The most frequent genetic alteration in papillary thyroid cancer
involves RET (rearranged during transfection), despite the absenceTable 1
The prevalence of genetic or molecular aberrations in various thyroid cancer types.
Thyroid tumour Frequency of
aberrations
Papillary thyroid cancer
RET/PTC 5–70
BRAF 30–80
RAS 10–15
MET 75
Follicular thyroid cancer
RAS 45
PPAX8 25–55
PTEN 0–27
PIK3CA 6–13
Aneuploidy 30–65
Hurthle cell cancer
mtDNA (CD) 100
grim-19 16
RET/PTC 26–57
CGH 62
Anaplastic thyroid cancer
P53 40–70
PIK3CA 12–23
RAS 6–50
BETA CATENIN 60of RET protein in thyroid follicular cells. The RET proto-oncogene is
located on chromosome 10q11.2 and encodes a receptor tyrosine
kinase. The frequency of RET/papillary thyroid cancer (RET/PTC)
alteration in papillary thyroid cancer varies between 5 and 70
percent.24–27 The rearrangements lead to the fusion of the RET
tyrosine kinase domain with the 50-terminal regions of heterolo-
gous genes, generating chimeric oncogenes designated as RET/PTC.
Twelve different chimeric protein arrangements have been
described that have been isolated from sporadic and radiation-
associated thyroid tumours and include RET/PTC 1–9, PCM1–RET,
ELKS–RET, and RFP–RET.28–30 RET/PTC 1, 2 and 3 are the most
common rearrangements in PTC, with the RET/PTC 3 variant asso-
ciated with more aggressive histotypes in post-radiation PTCs.31
RET rearrangements probably represent early events in thyroid
tumour pathogenesis, based on the fact that there is a high prev-
alence of RET/PTC transformation in papillary microcarcinomas and
lack of association with markers of clinical aggression.32
The ras oncogenes play an important role in the regulation of
cell growth and differentiation.33 Activating mutations in codons
12, 13 and 61 of the three ras genes, namely H-ras, K-ras and N-ras,
converts them into active oncogenes, which play an important role
in the pathogenesis of many tumours.34 The prevalence of ras
mutations is 10–15 percent in papillary cancers, particularly in
follicular-variant papillary thyroid cancer (FVPTC).35–37 Di Cristo-
faro et al. found nomutation of N-ras in classical PTC in comparison
to 25 percent seen in FVPTC.38 Tumours that express ras mutations
are associated with low rates of lymph node metastasis.39 The
tumours that harbour the ras mutations are prone to dedifferenti-
ation of the PTC into the anaplastic cancer type, in the presence of
additional mutations.40 In a retrospective study of 91 patients with
PTC, Hara et al. showed N-ras mutation to be associatedwith higher
recurrence rates and poor prognosis.41
The braf gene encodes for a protein belonging to the family of
protein kinases and is the most potent activator of the MAK kinase
pathway.42,43 More than 80% of all the BRAF mutations is the
T1799A transversion mutation44 and have been reported in many
human cancers, including that of thyroid cancer, ranging from 29 to
83%45,46 BRAF mutations have been shown in papillary cancer and
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medullary cancers, or benign thyroid neoplasms.47–50 Pooled data
from various studies have shown the prevalence of BRAF mutation
of to be 44 percent (810/1856) in PTC.50 The prevalence of BRAF
mutation is highest in tall-cell variant of papillary cancer (77%), 60%
in conventional PTC, and lowest in follicular-variant PTC (12%).50
Several studies have shown the association of BRAF mutation and
advanced stage,45,51 lymph node metastasis.46 Mutation in BRAF
may also be responsible for dedifferentiation of PTC into anaplastic
thyroid cancer.50
Another oncogene that play a role in thyroid carcinogenesis is
met, and encodes for a tyrosine kinase receptor for hepatocyte
growth factor/scatter factor (HGF/SF)52 which, when activated, acts
as a mitogenic factor and promotes cell motility and invasion.53
Ampliﬁcation is seen in 75 percent of papillary thyroid cancers54
and has been shown to be a marker for the tall-cell variant of
papillary carcinoma, which has an aggressive clinical course.55
7. Follicular thyroid carcinoma (FTC)
Follicular thyroid cancer is the second commonest cause of
differentiated thyroid cancer, accounting for 15 percent of all
thyroid cancers. They are common in women and is usually seen in
middle age to elderly individuals. Population based studies have
shown the incidence of FTC to be higher in iodine deﬁcient areas,
however, since the dietary iodine supplementation programme
introduced by the WHO, the frequency of FTC has declined.22,56
Rarely, follicular carcinoma may arise from a follicular adenoma.57
Dyshormonogenesis, a history of irradiation and Cowden’s
syndrome are predisposing factors for the formation of follicular
cancer. Unlike PTC, the cancers usually metastasize through the
blood stream into the bones, and lymph nodal disease is rare.57
The receptor tyrosine kinase (RTK), PI3K/Akt and MAPK path-
ways are prevalent in FTC, suggesting the role of these signalling
pathways mediated by growth factors and oncogenes like ras in
these tumours.58 Unlike PTC, RET and BRAF do not play any role in
the pathogenesis of follicular thyroid cancers. Follicular cancers
show a predominance of ras mutations, PAX8–PPARg rearrange-
ments and aneuploidy.
Point mutations of ras oncogenes are seen in about 40 percent of
thyroid tumours, with a predominance of N-ras over H-ras and K-
ras34; however a high rate of K-ras activation is seen in radiation
induced follicular cancers in comparison to the spontaneous type.59
In a recent study by Rivera et al. N-ras mutations were the most
frequent oncogenic activation in 45 percent of the follicular thyroid
tumours with features of high grade.60 The presence of ras muta-
tion in both follicular adenomas and carcinomas may suggest their
role in early steps of thyroid carcinogenesis. Using in vivo models
Miller et al. showed that simultaneous activation of K-ras with P13K
signallingwas necessary for oncogenic transformation into invasive
and metastatic cancers.61 Follicular cancers that harbour ras
mutations may be at a risk of dedifferentiating into anaplastic
thyroid cancers.62,63 Mutations of ras gene are associated with poor
histological features and poor patient survival.64
Pax8 encodes a transcription factor essential for the genesis of
the thyroid follicular cell lineage and thyroid-speciﬁc gene
expression.65,66 Kroll et al. in 2000 identiﬁed PAX8–PPARg gene
fusion in a signiﬁcant portion of follicular carcinomas, some with
a cytogenetically detectable translocation t(2;3)(q13;p25) (Kroll
et al. 2000). This was initially thought to be a speciﬁc molecular
marker of FTC,67 however, further studies showed the prevalence to
be about 26–56% in follicular carcinomas and in 0–13% of follicular
adenomas, 0–3% of Hu¨rthle cell carcinomas, and 0–1% papillary
carcinomas.68,69 No point mutations of PPARg gene have been
shown in thyroid carcinomas and the mechanism of PPARgactivation is believed to be chromosomal rearrangement.70 PPARg
activation may be involved with vascular invasion,71 and this may
be due to up-regulation of target genes like angiopoietin-like 4 and
aquaporin 7.72 Underexpression of peroxisome proliferator-acti-
vated receptor (PPAR) gamma in Pax-8/PPAR gamma-negative
thyroid tumours is associated with dedifferentiation at later stages
of tumour development and progression.73 In one study, positive
PPARg immunolabelling was associated with favourable prognosis
(females, low grade tumours and low risk of metastasis).74
Aneuploidy or aberrant chromosome number has been recog-
nized as a common characteristic of cancer cells for many years and
has been implicated in tumourigenesis. Aneuploidy can either act
as an oncogene or as a tumour suppressor gene based on the cell
type and the presence or absence of additional genetic damage.75
Aneuploidy is observed in about 12–24 percent of adenomas and
30–64 percent of carcinomas.76–78 There is a higher incidence of
aneuploidy in widely invasive carcinomas in comparison to the
minimally invasive carcinomas.79 Using ﬂuorescence in situ
hybridization analysis (FISH), Roque et al. showed an increase in
percentage of gain of chromosome 7 and 12 in the different
phenotypes analysed. The percentage was low for goiters, slightly
higher in adenomas and highest in carcinomas (18, 52 & 66 for
chromosome 7; 9, 43 and 66 for chromosome 12).80 This suggests
a role of the increasing frequency of polysomies of chromosomes 7
and 12 in the multistep pathogenesis of thyroid neoplasms.
8. PTEN
Phosphate and tensin homolog (PTEN) gene is a tumour
suppressor gene by negatively regulating the P13K signalling
pathway, and is activated in many human cancers. In Cowden’s
syndrome, inactivating mutation of PTEN has been shown to be the
cause of the disease.81 In sporadic follicular thyroid cancer, somatic
intragenic mutations of PTEN are rare.82–84 However loss of
heterozygosity at 10q23 of the PTEN gene has been associated with
follicular thyroid carcinomas.82,85 The frequency of PTENmutations
have been reported to be a higher frequency in comparison to
follicular cancer, implying the role of the gene in dedifferentiation
from differentiated cancer.83,86–88
9. PI3KCA
The phosphatidylinositol 3-kinase (PI3K) pathway involves
signal transduction by tyrosine kinase receptors and promotes
cancer cell proliferation and survival. The gene encoding for PI3KCA
is either ampliﬁed, or undergo heterozygous point mutations in
cancers.89,90 The frequency of point mutations in follicular cancer
has been reported between 6 and 13 percent.86,91 PTEN gene when
silenced with genetic alterations in PI13K pathway may contribute
to progression of thyroid cancers.92
10. Hurthle cell carcinoma
Hurthle cell carcinoma accounts for 2–8 percent of differenti-
ated thyroid cancers and are characterised by the presence of
Hurthle cells, which are large eosinophilic thyroid cells that contain
a large number of mitochondria.93 These tumours tend to be more
aggressive than follicular thyroid cancers, metastasize often to
lymph nodes and usually do not take up radioiodine. Previous
exposure to radiation,94 and somatic gene mutations are risk
factors for the development of Hurthle cell cancer. These tumours
tend to be seen in the ﬁfth and sixth decade of life, with an
increased female preponderance. Most common presentation is
with a solitary nodule, however some patients present with nodal
disease, and a few with compressive symptoms.
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proﬁle in comparison to the follicular thyroid cancers. Hurthle cells
are characterised by the presence of abnormal mitochondria,
usually associated with defective mitochondrial DNA (mtDNA) and
intranuclear genes. Alterations in RET/PTC and chromosomal
aberrations have also been described in Hurthle cell tumours.
11. Mitochondrial DNA
Mitochondrial DNA contains 37 genes that are responsible for
normal mitochondrial function and are prone to somatic mutations
that may result in cancer. Somatic mutations of mtDNA have been
described in Hurthle cell tumours.95 Maximo et al. showed the
presence of mtDNA in both adenomas and carcinomas, with
a higher proportion of deleted DNA in carcinomas. More than
80 percent of mutations seen tend to be somatic transition
mutations.95 The mutations are probably associated with disrup-
tion of oxidative phosphorylation, linked to increase in the
2 mitochondrial genes ND2 and ND5.96
12. GRIM-19
GRIM-19 (Gene associated with retinoid-interferon-b-induced
mortality) is an important protein that regulates interferon-b-
Retinoic acid-induced cell death. Overexpression of GRIM-19 is
associated with cell death and its suppression promotes cell
growth.97 GRIM-19 is an important gene necessary for the function
of the mitochondrial respiratory chain complex I assembly and
activity. Mutations in genes directly or indirectly affecting
mitochondrial function could be the cause of the increase in
mitochondrial number in Hurthle cell tumours.98 The presence of
GRIM-19mutations have been reported only in Hurthle cell lesions,
with none reported in non Hurthle cell lesions and this may explain
their role in the pathogenesis of these tumours.99 Mutations
identiﬁed in HCC byMaximo et al. were located at codons 26, 83, 88
(exon 1) and 198 (exon 5) of GRIM-19.99
13. Chromosomal aberrations
Chromosomal aberrations by comparative genomic hybridiza-
tion (CGH) are common in Hurthle cell neoplasms. In a study of 28
Hurthle cell tumours themost common chromosomal gainwas that
of 5p (29 percent) and losswas that of 2q and 9q.100Widely invasive
carcinomas and poorly differentiated carcinomas was associated
with more chromosomal gains than that of well differentiated type,
and this correlated with the stage of the disease.100 With the
progression from benign to malignant phenotype, the incidence of
trisomy 7 and 12 increases, thus implying the role in multistep
tumourigenesis.80 Gains on chromosome 12 are more common in
Hurthle cell carcinomas than in Hurthle cell adenomas, especially in
patients with recurrent disease, again highlighting their association
with phenotypical progression to malignant state.100
14. ret/PTC
Alterations of ret/PTC is commonly associated with papillary
thyroid cancer and not usually seen in classical Hurthle cell cancers.
However, Hurthle cell carcinomas with papillary features shows
ret/PTC alterations, with RET/PTC 1 the most common
rearrangement.101
15. Anaplastic thyroid cancer
Anaplastic thyroid cancer is the least common andmost lethal of
all thyroid cancers, with only a mean survival of 6 months afterdiagnosis.102 They commonly present with a rapidly enlarging
mass, and commonly inﬁltrate the local structures, namely the
trachea, oesophagus and the neck vessels. Lymph node involve-
ment is commonly seen early in the disease. The cancer may arise
either de novo, in long standing goitre or in patients with previous
well differentiated thyroid carcinoma.103,104 Anaplastic cancers do
not concentrate iodine and thyroglobulin. Histologically the most
common type is the giant cell type, composed of large cells with
cytological pleomorphism.
16. p53
The p53 suppressor gene, located on chromosome 17p13, plays
an important role in the development of cancer. Studies have
shown that p53 belongs to a multigene family of that also includes
p63 and p73.105,106 The p53 gene encodes a nuclear phosphoprotein
that acts as a transcription factor, and plays an important role as
mediator of cell cycle arrest in G1 and G2 phase. Inactivating
mutations of p53 have been described in 50% of human malig-
nancies, and the majority of the mutations are in the exons 5–8.107
However in the thyroid gland, p53 mutations have been shown in
40–62% of undifferentiated carcinomas108,109 and only 5–10% in
other carcinomas.110 The mutations of p53 or increased expression
of p53 protein is associated with the progression from differenti-
ated to anaplastic carcinoma.110–112 Thus, presence of p53 muta-
tions is a late event in thyroid cancer progression. In addition to
thyroid cancer progression, p53 inactivation has also been impli-
cated in chemoresistance.113,114 Gene therapy using the E1B gene-
defective adenovirus (ONYX-15), which only replicates in cells
deﬁcient in p53, have been used to kill anaplastic cancer cells, both
in vitro and in vivo.115,116
17. PIK3CA
P13K pathway is a main regulator of cell growth, metabolism
and survival. PIK3CA encodes for a catalytic subunit of P13K and is
located on the chromosome 3q26.3. Mutation of PIK3CA have been
shown in 12–23 percent of anaplastic thyroid cancer.58,117,118 In 18
out of 20 cases of anaplastic cancer studied, coexisting areas of
differentiated cancer showed no expression of PIK3CA unlike the
anaplastic areas.117 Akt, a downstream effector of the PI3K gene, has
been shown to be activated in up to 93 percent of cases.117,118 PTEN
a negative regulator of PI3K is down-regulated in 37 percent of
differentiated thyroid cancers, with no expression in anaplastic
cancer.87
18. MAPK effector genes
Ras and BRAF are oncoproteins that activate the MAPK kinase
and ERK pathway, and aberrations of signalling in this pathway
leads to tumour formation, transformation and maintenance. Ras
mutations are seen in both differentiated and undifferentiated
cancer types, with a frequency of 6–50 percent in anaplastic
cancer.40,64,119,120 The frequency of BRAF mutations in anaplastic
cancer ranges from 0 to 50 percent.51 In tumours that harbour both
papillary and anaplastic thyroid cancer, the proﬁle of BRAF alter-
ations tends to be similar, thereby supporting the hypothesis that
anaplastic cancers arise from well differentiated cancer.121,122
19. Wnt pathway genes
Beta catenin is a gene that is involved with Wnt signalling and
cell adhesion and deregulation is associated with the development
and progression of cancer.123 Well differentiated cancers do not
show any abnormalities in the signalling pathways involving
Table 2
The various agents used as agents for various signalling pathways in thyroid cancers.
Agent Target References
ZD6474 RET, EGFR 132
PP1 RET 132
PP2 RET 132
Sorafenib Raf, RET, KIT, PGDFR, VEGFR, BRAF 133,134
Tipifarnib Farnesyltransferase 133
Sunitinib (SU11248) RET, PDGF, VEGFR 135
AAL-881 and LBT-613 RAF, BRAF, RET 136
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61 percent of cases126 and 32 percent of poorly differentiated
cancers.124 Galectin-3, a b-galactoside-binding protein is a binding
partner of beta catenin of the Wnt pathway. Cytoplasmic expres-
sion of galectin-3 has been to be absent in anaplastic cancers in
comparison to well differentiated thyroid cancers,127,128 implying
the role of these pathways in thyroid cancer progression. In a study
of 5 cases of anaplastic thyroid cancer with areas of well differen-
tiated tumours type, areas of dedifferentiated tissues showed no
immunolabelling for galectin-3, with strongly reactive labelling in
differentiated areas.129
20. Molecular proﬁling as a preoperative tool for diagnosis
Currently FNAC is the most important tool to diagnose a nodule
as benign or malignant to aid the surgeon in the deﬁnitive treat-
ment. There is clearly evidence of differential expression of various
molecular genetic markers between benign and malignant thyroid
nodules, and between various thyroid cancer subtypes, discussed in
the previous sections. Recentlymolecular proﬁling has been used in
combination with FNAC, and it has shown improved prediction of
malignancy and diagnostic accuracy.130,131
21. Molecular pathways as therapeutic targets
There is no doubt about the role of signalling pathways, onco-
genes and tumour suppressor genes in the molecular pathogenesis
and progression of thyroid cancer. They also have been used as
markers of prognosis. Recent advances have targeted these
signalling pathways, predominantly the MAPK pathways. The
patients with well differentiated cancers respond well to conven-
tional treatment of thyroidectomy and radioiodine ablation.
However the poorly differentiated or anaplastic cancers do not
respond to radioiodine and may be the potential targets for such
treatments. Various compounds have been used to target different
key molecular pathways, and includes those of RET, BRAF and
growth factors. Most of the studies are limited to Phase I or II trials
or in vitro models. Some of the compounds currently used in
targeted therapies are illustrated in Table 2.
22. Conclusions
To summarize, thyroid tumours develop as a result of sequential
accumulation of alterations in the genes involved in the control of
cell proliferation, differentiation or death according to the
multistep carcinogenesis theory. The early steps of thyroid cancer
formation are the result of activation of proto-oncogenes,
oncogenes and growth factors. With further mutations involving
tumours suppressor genes differentiated cancers progress into the
dedifferentiated state. Some of the molecular changes are speciﬁc
to certain cancer types, which makes it possible to ascertain both
diagnostic and prognostic information. The understanding of the
molecular aspects of the disease including the various signalling
pathways has the potential to offer target based therapies.Conﬂict of interest
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